Takeda Pharmaceutical Co Ltd (JP:4502)

:4502

4502

Takeda Pharmaceutical Co

RESEARCH TOOLSreports

Want to see JP:4502 full AI Analyst Report?

Takeda Pharmaceutical Co (4502) Stock Forecast & Price Target

7 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4502 Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Takeda

Pharmaceutical Co

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4502 Stock 12 Month Forecast

Average Price Target

¥6,900.00

▲(63.43% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Takeda Pharmaceutical Co in the last 3 months. The average price target is ¥6,900.00 with a high forecast of ¥6,900.00 and a low forecast of ¥6,900.00. The average price target represents a 63.43% change from the last price of ¥4,222.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4050":"¥4,050","6901":"¥6,901","4762.75":"¥4,762.8","5475.5":"¥5,475.5","6188.25":"¥6,188.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥7K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4050,4762.75,5475.5,6188.25,6901],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5888,5965.846153846154,6043.692307692308,6121.538461538462,6199.384615384615,6277.2307692307695,6355.076923076923,6432.923076923077,6510.7692307692305,6588.615384615385,6666.461538461538,6744.307692307692,6822.153846153846,{"y":6900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5888,5965.846153846154,6043.692307692308,6121.538461538462,6199.384615384615,6277.2307692307695,6355.076923076923,6432.923076923077,6510.7692307692305,6588.615384615385,6666.461538461538,6744.307692307692,6822.153846153846,{"y":6900,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5888,5965.846153846154,6043.692307692308,6121.538461538462,6199.384615384615,6277.2307692307695,6355.076923076923,6432.923076923077,6510.7692307692305,6588.615384615385,6666.461538461538,6744.307692307692,6822.153846153846,{"y":6900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4331.93,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4200.31,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4108.081,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4221.447,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4051.397,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4293.501,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4187.054,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4081.887,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4431.791,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4752.209,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5250.527,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5694.787,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5888,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target¥6,900

Average Price Target¥6,900

Lowest Price Target¥6,900

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Miki Sogi

Bernstein

¥6,900

Buy

63.43%

Upside

Reiterated

04/14/26

Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)

Shinichiro Muraoka

Morgan Stanley

¥6,200

Buy

46.85%

Upside

Initiated

01/13/26

Takeda resumed with an Overweight at Morgan StanleyTakeda resumed with an Overweight at Morgan Stanley

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥5,200→¥5,000

Buy

18.43%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

¥5,500

Buy

30.27%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

¥5,400→¥5,300

Buy

25.53%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

¥5,135

Buy

21.62%

Upside

Reiterated

05/21/25

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Kelly Shi

Jefferies

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Miki Sogi

Bernstein

¥6,900

Buy

63.43%

Upside

Reiterated

04/14/26

Analysts Are Bullish on Top Healthcare Stocks: Takeda Pharmaceutical Co (TKPHF), Immunocore Holdings (IMCR)

Shinichiro Muraoka

Morgan Stanley

¥6,200

Buy

46.85%

Upside

Initiated

01/13/26

Takeda resumed with an Overweight at Morgan StanleyTakeda resumed with an Overweight at Morgan Stanley

Unknown Analyst

Macquarie

Not Ranked

Macquarie

¥5,200→¥5,000

Buy

18.43%

Upside

Reiterated

10/14/25

Macquarie Remains a Buy on Takeda Pharmaceutical Co (TKPHF)

Koichi Mamegano

Bank of America Securities

¥5,500

Buy

30.27%

Upside

Reiterated

09/08/25

Promising Phase 3 Results for Takeda's Oveporexton Boost Buy Rating

Hiroyuki Matsubara

Nomura

¥5,400→¥5,300

Buy

25.53%

Upside

Reiterated

06/12/25

Nomura Keeps Their Buy Rating on Takeda Pharmaceutical Co (TKPHF)

Michael Nedelcovych

TD Cowen

¥5,135

Buy

21.62%

Upside

Reiterated

05/21/25

Unknown Analyst

Bloomberg Ind.

Not Ranked

Bloomberg Ind.

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Kelly Shi

Jefferies

¥5,500→¥5,100

Buy

20.80%

Upside

Reiterated

05/08/25

Analysts Offer Insights on Healthcare Companies: Takeda Pharmaceutical Co (Other OTC: TKPHF), Opus Genetics (NASDAQ: IRD) and CareCloud (NASDAQ: CCLD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Takeda Pharmaceutical Co

3 Months

xxx

Success Rate

2/2 ratings generated profit

Average Return

+11.80%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +11.80% per trade.

1 Year

Koichi MameganoBank of America Securities

Success Rate

7/7 ratings generated profit

Average Return

+26.41%

Copying Koichi Mamegano's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.41% per trade.

2 Years

xxx

Success Rate

2/2 ratings generated profit

Average Return

+37.90%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +37.90% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4502 Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4502 has received 2 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 4502 average Analyst price target in the past 3 months is 6,900.00.

Each month's total comprises the sum of three months' worth of ratings.

4502 Financial Forecast

4502 Earnings Forecast

Next quarter’s earnings estimate for 4502 is -¥24.02 with a range of -¥38.53 to -¥9.50. The previous quarter’s EPS was ¥65.74. 4502 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 4502 has Performed in-line its overall industry.

4502 Sales Forecast

Next quarter’s sales forecast for 4502 is ¥1.12T with a range of ¥1.11T to ¥1.15T. The previous quarter’s sales results were ¥1.19T. 4502 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 4502 has Performed in-line its overall industry.

4502 Stock Forecast FAQ

What is JP:4502’s average 12-month price target, according to analysts?

Based on analyst ratings, Takeda Pharmaceutical Co Ltd’s 12-month average price target is 6,900.00.

What is JP:4502’s upside potential, based on the analysts’ average price target?

Takeda Pharmaceutical Co Ltd has 63.43% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Takeda Pharmaceutical Co Ltd a Buy, Sell or Hold?

Takeda Pharmaceutical Co Ltd has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Takeda Pharmaceutical Co Ltd’s share price target?

The average share price target for Takeda Pharmaceutical Co Ltd is 6,900.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ¥6,900.00 ,and the lowest forecast is ¥6,900.00. The average share price target represents 63.43% Increase from the current price of ¥4,222.

What do analysts say about Takeda Pharmaceutical Co Ltd?

Takeda Pharmaceutical Co Ltd’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Takeda Pharmaceutical Co Ltd?

To buy shares of JP:4502, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Takeda Pharmaceutical Co (4502) Stock Forecast & Price Target

4502 Analyst Ratings

4502 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Takeda Pharmaceutical Co

4502 Analyst Recommendation Trends

4502 Financial Forecast

4502 Earnings Forecast

4502 Sales Forecast

4502 Stock Forecast FAQ

Detailed List of Analyst Forecasts